Last reviewed · How we verify
AZD8529
AZD8529 is a selective adenosine A2A receptor antagonist.
AZD8529 is a selective adenosine A2A receptor antagonist. Used for Multiple myeloma.
At a glance
| Generic name | AZD8529 |
|---|---|
| Also known as | AZD-8529 |
| Sponsor | AstraZeneca |
| Drug class | adenosine A2A receptor antagonist |
| Target | A2A receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AZD8529 works by blocking the action of adenosine at the A2A receptor, which is involved in the regulation of inflammation and immune responses. This blockade is thought to have anti-inflammatory effects and may help to reduce the severity of certain diseases.
Approved indications
- Multiple myeloma
Common side effects
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
- The Study of AZD8529 for Smoking Cessation in Female Smokers (PHASE2)
- The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics (PHASE1)
- The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers (EARLY_PHASE1)
- Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients (PHASE2)
- AZD8529 Single Ascending Dose Study in Healthy Japanese Subjects (PHASE1)
- AZD8529 Multiple Ascending Dose Study in Healthy Subjects (PHASE1)
- AZD8529 Single Ascending Dose Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD8529 CI brief — competitive landscape report
- AZD8529 updates RSS · CI watch RSS
- AstraZeneca portfolio CI